As of 2026-01-08, the Relative Valuation of Alnylam Pharmaceuticals Inc (ALNY) is 7.47 USD. This relative valuation is based on P/E multiples. With the latest stock price at 422.50 USD, the upside of Alnylam Pharmaceuticals Inc based on Relative Valuation is -98.2%.
The range of the Relative Valuation is 4.88 - 14.01 USD.
| Range | Selected | |
| Trailing P/E multiples | 14.8x - 17.1x | 16.0x |
| Forward P/E multiples | 16.2x - 42.5x | 29.4x |
| Fair Price | 4.88 - 14.01 | 7.47 |
| Upside | -98.8% - -96.7% | -98.2% |
| Date | P/E |
| 2026-01-08 | 1,269.15 |
| 2026-01-07 | 1,281.22 |
| 2026-01-06 | 1,232.40 |
| 2026-01-05 | 1,206.41 |
| 2026-01-02 | 1,213.51 |
| 2025-12-31 | 1,205.87 |
| 2025-12-30 | 1,204.65 |
| 2025-12-29 | 1,209.41 |
| 2025-12-26 | 1,214.78 |
| 2025-12-24 | 1,215.08 |
| 2025-12-23 | 1,209.05 |
| 2025-12-22 | 1,236.43 |
| 2025-12-19 | 1,213.69 |
| 2025-12-18 | 1,200.98 |
| 2025-12-17 | 1,189.04 |
| 2025-12-16 | 1,186.22 |
| 2025-12-15 | 1,187.22 |
| 2025-12-12 | 1,205.56 |
| 2025-12-11 | 1,251.29 |
| 2025-12-10 | 1,226.52 |
| 2025-12-09 | 1,259.12 |
| 2025-12-08 | 1,304.03 |
| 2025-12-05 | 1,389.24 |
| 2025-12-04 | 1,411.13 |
| 2025-12-03 | 1,435.24 |
| 2025-12-02 | 1,409.89 |
| 2025-12-01 | 1,378.44 |
| 2025-11-28 | 1,368.35 |
| 2025-11-26 | 1,349.82 |
| 2025-11-25 | 1,303.36 |
| 2025-11-24 | 1,316.79 |
| 2025-11-21 | 1,323.31 |
| 2025-11-20 | 1,351.85 |
| 2025-11-19 | 1,397.25 |
| 2025-11-18 | 1,401.92 |
| 2025-11-17 | 1,396.58 |
| 2025-11-14 | 1,362.07 |
| 2025-11-13 | 1,376.66 |
| 2025-11-12 | 1,372.93 |
| 2025-11-11 | 1,370.53 |
| 2025-11-10 | 1,339.45 |
| 2025-11-07 | 1,342.48 |
| 2025-11-06 | 1,335.78 |
| 2025-11-05 | 1,317.79 |
| 2025-11-04 | 1,284.16 |
| 2025-11-03 | 1,316.31 |
| 2025-10-31 | 1,382.93 |
| 2025-10-30 | 1,363.28 |
| 2025-10-29 | 1,460.41 |
| 2025-10-28 | 1,443.19 |